Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Henry Houlden practices in London, United Kingdom. Houlden is rated as an Elite expert by MediFind in the treatment of Harding Ataxia. He is also highly rated in 142 other conditions, according to our data. His top areas of expertise are Drug Induced Dyskinesia, Harding Ataxia, Chorea, Paraplegia, and Deep Brain Stimulation.
Nicholas Wood practices in London, United Kingdom. Wood is rated as an Elite expert by MediFind in the treatment of Harding Ataxia. He is also highly rated in 40 other conditions, according to our data. His top areas of expertise are Harding Ataxia, Parkinson's Disease, Drug Induced Dyskinesia, Deep Brain Stimulation, and Liver Transplant.
Jeremy Schmahmann is a Neurologist in Boston, Massachusetts. Schmahmann has been practicing medicine for over 43 years and is rated as an Elite expert by MediFind in the treatment of Harding Ataxia. He is also highly rated in 52 other conditions, according to our data. His top areas of expertise are Acute Cerebellar Ataxia, Spinocerebellar Ataxia, Olivopontocerebellar Atrophy, and Drug Induced Dyskinesia. Schmahmann is currently accepting new patients.
Summary: The aim of the research is to improve motor function in people with cerebellar ataxia by using neuroimaging methods and mental imagery to exercise motor networks in the brain. The relevance of this research to public health is that results have the potential to reduce motor deficits associated with cerebellar atrophy, thereby enhancing the quality of life and promoting independence.
Summary: The primary objective of this study is to evaluate the safety and tolerability of multiple ascending doses of BIIB132 administered via intrathecal (IT) injection to participants with spinocerebellar ataxia type 3 (SCA3). The secondary objective of this study is to characterize the multiple-dose pharmacokinetics (PK) of BIIB132 administered via IT injection to participants with SCA3.